Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18419480 | 0.89 | MAPT (0.62) | MAPTTDP1PKMCA12CA1 | |
| Syringate SCHEMBL30725929 | 0.88 | PKM (0.53) | MAPTTDP1PKMCA12CA1 | |
| SCHEMBL5242300 | 0.85 | PKM (0.55) | MAPTTDP1PKMCA12CA1 | |
| SCHEMBL4903560 | 0.85 | PKM (0.58) | MAPTTDP1PKMLCKFYN | |
| SCHEMBL9903881 | 0.84 | LMNA (0.46) | MAPTTDP1PKMCA12CA1 | |
| Ammonia Solution, Strong SCHEMBL27859010 | 0.84 | PKM (0.57) | MAPTTDP1PKMLCKFYN | |
| SCHEMBL9716404 | 0.84 | TDP1 (0.47) | MAPTTDP1PKMCA12CA1 | |
| SCHEMBL505418 | 0.81 | LCK (0.56) | MAPTTDP1PKMLCKFYN | |
| SCHEMBL18669122 | 0.81 | KDM4E (0.54) | MAPTTDP1PKMCA12CA1 | |
| SCHEMBL27601741 | 0.79 | LCK (0.53) | MAPTTDP1PKMCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663804-B2 | Method of treating polyester textile | NOVOZYMES A/S (DK) | 2017-05-30 | — | — | US | claimed |
| EP-2589629-B1 | Enzyme curable alkyd composition | ROHM & HAAS (US) | 2016-12-14 | — | — | EP | claimed |
| EP-2036151-B1 | NOVEL THIN FILM STRUCTURES | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2016-08-10 | — | — | EP | claimed |
| US-9394555-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a dioxy compound and uses thereof | NOVOZYMES, INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20130157317-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Dioxy Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2013-06-20 | — | — | US | claimed |
| US-12600996-B2 | Carbohydrate binding module variants and hybrid polypeptides comprising same | NOVOZYMES A/S (DK) | 2026-04-14 | — | — | US | disclosed |
| US-20250092434-A1 | CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOF | NOVOZYMES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12195776-B2 | Cellulolytic enzyme compositions and uses thereof | NOVOZYMES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240376507-A9 | CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOF | NOVOZYMES, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4458964-A2 | CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | Novozymes A/S (DK) | 2024-11-06 | — | — | EP | disclosed |
| EP-3586610-B1 | POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-09-25 | — | — | EP | disclosed |
| EP-3739045-B1 | CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-08-14 | — | — | EP | disclosed |
| WO-2012030845-A2 | POLYPEPTIDES HAVING BETA-GLUCOSIDASE ACTIVITY, BETA-XYLOSIDASE ACTIVITY, OR BETA-GLUCOSIDASE AND BETA-XYLOSIDASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES A/S (DK) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012021408-A1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A DIOXY COMPOUND AND USES THEREOF | NOVOZYMES, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120023623-A1 | Polypeptides having beta-glucosidase activity and polynucleotides encoding same | NOVOZYMES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012003379-A1 | POLYPEPTIDES HAVING BETA-GLUCOSIDASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES A/S (DK) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011126897-A2 | METHODS FOR ENHANCING BY-PRODUCTS FROM FERMENTATION PROCESSES | NOVOZYMES A/S (DK) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123505-A1 | PROCESSES OF PRODUCING A FERMENTATION PRODUCT | NOVOZYMES NORTH AMERICA, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| CN-1107493-C | Antibacterial toothpaste | WARNER LAMBERT CO (US) | 2003-05-07 | — | — | CN | disclosed |
| CN-1153470-A | Antibacterial toothpaste | WARNER LAMBERT CO (US) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600996-B2 | Carbohydrate binding module variants and hybrid polypeptides comprising same | QPCTL, DNTT, RNGTT | MAPT 1179/4885TDP1 623/4885PKM 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.